Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Amine Reactive Sensor

By Drug Discovery Trends Editor | April 30, 2009

Axela Inc. introduced the dotLab Amine Reactive Sensor for stable covalent coupling of affinity reagents, such as antibodies, for use with the Axela dotLab System. The sensor directly links capture species covalently, thereby eliminating the need for offline conjugation, and reducing capture protein requirements 50-fold. The sensors are compatible with regeneration for increased throughput or rapid comparative experiments. The sensor’s lidless format makes sample recovery possible for offline mass spectrometry analysis.

Customers can order from different Amine Reactive Sensor formats: Sensor Kit, 12 sensors and a tubing set; Starter Kit, 12 sensors, tubing set, model assay test reagents, and buffers; and Activation Kit, activation reagents and buffers for amine-directed coupling.

The dotLab System employs a novel technology for performing immunoassays and the real-time study of protein interactions. The instrument automatically delivers samples and reagents to a disposable dotLab Sensor where binding events are quantitatively measured in real time. The system expands the utility of traditional immunoassays, and makes unique categories of diagnostic markers accessible for study.

Axela Inc.

Published in Drug Discovery & Development magazine: Vol. 12, No. 5, May, 2009, p.35.


Filed Under: Drug Discovery

 

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE